Efficacy and safety of an inactivated vaccine against Salmonid alphavirus (family Togaviridae )

Highlights ► We present efficacy and safety data from an inactivated vaccine against Salmonid alphavirus. ► The vaccine provides almost complete protection against infection in intraperitoneal and cohabitant challenge models. ► Significant protection is found in a field trial. ► The antigen can be i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2012-08, Vol.30 (38), p.5688-5694
Hauptverfasser:	Karlsen, Marius, Tingbø, Terje, Solbakk, Inge-Tom, Evensen, Øystein, Furevik, Anette, Aas-Eng, Anne
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Alphavirus Animals Aquaculture bacterial antigens Cavities Combined vaccines epizootic diseases Epizootics field experimentation Fish fish culture Fish Diseases - epidemiology Fish Diseases - immunology Fish Diseases - prevention & control Fish Diseases - virology Fish vaccine Genetic diversity genetic variation industry Infection Melanization Mortality Norway - epidemiology Pancreas pancreas disease Safety Salmo salar Salmon Salmonid alphavirus Salmonidae Survival Survival Analysis Togaviridae Togaviridae - immunology Togaviridae - isolation & purification Togaviridae - pathogenicity Togaviridae Infections - epidemiology Togaviridae Infections - prevention & control Togaviridae Infections - veterinary Togaviridae Infections - virology Vaccines Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - adverse effects Vaccines, Inactivated - immunology Viral Vaccines - administration & dosage Viral Vaccines - adverse effects Viral Vaccines - immunology viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► We present efficacy and safety data from an inactivated vaccine against Salmonid alphavirus. ► The vaccine provides almost complete protection against infection in intraperitoneal and cohabitant challenge models. ► Significant protection is found in a field trial. ► The antigen can be included in polyvalent vaccines. ► The vaccine has an attractive safety profile.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2012.05.069